RxDoctor Payments Data

Brenda Corbin

Family · Starke, FLNPI 1629279278

Payments from drug & device makers

$9,018in general payments, 2019–2025

Across 327 payments — averaging $27.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Inari Medical, Inc.$1K
  • AbbVie$1K
  • Amgen$902
  • Lilly USA, LLC$641
  • Pfizer$524
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,018100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,018 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$74,400
Medicare patients
313
Services billed
1,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$35,644
MounjaroTirzepatide11$26,243
EliquisApixaban28$23,458
XareltoRivaroxaban11$12,523
FarxigaDapagliflozin Propanediol11$10,595
SynthroidLevothyroxine Sodium13$1,293
Rosuvastatin Calcium105$1,276
Olmesartan Medoxomil41$1,058
Atorvastatin Calcium145$806
Levothyroxine Sodium96$785
Gabapentin33$784
Albuterol Sulfate HfaAlbuterol Sulfate12$754
Metoprolol Succinate59$671
Omeprazole34$616
Escitalopram Oxalate46$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$364$35,64418 claims
Lilly USA, LLCMounjaro$641$26,24311 claims
PfizerEliquis$524$23,45828 claims
Johnson & JohnsonXarelto$56$12,52311 claims
AstraZenecaFarxiga$1,166$10,59511 claims
AbbVieSynthroid$1,037$1,29313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Starke

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →